Rabbit Anti-Human URI1 monoclonal antibody, clone TQ326

Paired indoor and outdoor measurements of 16 NPAHs and 5 OPAHs in PM2.5 were conducted at urban and suburban sites during January 2016 in Jinan, China. The concentrations of both indoor and outdoor NPAHs and OPAHs were higher at the urban site compared with the suburban site. 9N-ANT (16-42%), 2 + 3N-FLA (15-51%), 2N-PYR (6-20%), and 1N-PYR (4-6%) were the dominant NPAHs at all sites, and 9-FO (61-81%) was the most abundant OPAHs. Solid fuel combustion, motor vehicle exhausts, and secondary generation were the main sources of the PAH derivatives in this study area. The I/O ratios of 90% of NPAHs and OPAHs at the first urban indoor site (abbreviated as URI1, Green Tree Inn) and the suburban indoor site (abbreviated as SUI, the Seven Star Hotel) were < 1.00 indicating that many of the compounds measured indoors originated from outdoor sources. At the second urban indoor site (abbreviated as URI2, Shandong University Hotel), the I/O ratios of 2-and 3-ring NPAHs and OPAHs were > 1.00, which was likely due to cooking activities occurring near the measurement site. Measurements of outdoor 2 + 3N-FLA/1N-PYR revealed mainly primary emission at the urban site and secondary sources at the suburban site, the average ratios were 3.76 and 12.22, respectively. The average ratio of 2 + 3N-FLA/2N-PYR at all sites was 3.3, indicating that the OH-initiated reaction was the dominant secondary formation pathway. Nighttime ratios of 2 + 3N-FLA/1N-PYR were significantly higher than the daytime ratios at all sites. The difference was especially pronounced during heavily polluted conditions at the suburban site, which suggests that heavy pollution and nighttime conditions promote secondary production. Additionally, the cancer risk was highest in urban outdoor (abbreviated as URO) when the population expose to the level as the outdoor air in the urban. The risk suggested that adults may be at a higher cancer risk.

Objectives. Readily apparent cyclin El expression occurs in 50% of HGSOC, but only half are linked to 19q12 locus amplification. The amplified/cyclin E1(hi) to subset has intact BRCA1/2, unfavorable outcome, and is potentially therapeutically targetable. We studied whether non-amplified/cyclin E1(hi) HGSOC has similar characteristics. We also assessed the expression of cyclin El degradation-associated proteins, FBXW7 and USP28, as potential drivers of high cyclin El expression in both subsets. Methods. 262 HGSOC cases were analyzed by in situ hybridization for 19q12 locus amplification and immunohistochemistry for cyclin El, URI1 (another protein encoded by the 19812 locus), FBXW7 and USP28 expression. Tumors were classified by 19q12 amplification status and correlated to cyclin El and URI1 expression, BRCA1/2 germline mutation, FBXW7 and USP28 expression, and clinical outcomes. Additionally, we assessed the relative genomic instability of amplified/cyclin E1(hi) and non-amplified/cyclin E1(hi) groups of HGSOC datasets from The Cancer Genome Atlas. Results. Of the 82 cyclin El hi cases, 43 (52%) were amplified and 39 (48%) were non-amplified. Unlike amplified tumors, non-amplified/cyclin E1(hi) tumor status was not mutually exclusive with gBRCA1/2 mutation. The non-amplified/cyclin E1(hi) group had significantly increased USP28, while the amplified/cyclin E1(hi) cancers had significantly lower FBXW7 expression consistent with a role for both in stabilizing cyclin E1. Notably, only the amplified/cyclin E1(hi) subset was associated with genomic instability and had a worse outcome than nonamplified/cyclin E1(hi) group. Conclusions. Amplified/cyclin E1(hi) and non-amplified/cyclin E1(hi) tumors have different pathological and biological characteristics and clinical outcomes indicating that they are separate subsets of cyclin E1(hi) HGSOC. (C) 2018 Published by Elsevier Inc.